1
TÍTULO: Gastrointestinal Events and Management Strategies for Patients with Acute Myeloid Leukemia (AML) in First Remission Receiving CC-486 Maintenance Therapy in the Randomized, Placebo-Controlled, Phase III QUAZAR AML-001 Trial  Full Text
AUTORES: Farhad Ravandi; Christopher Pocock; Dominik Selleslag; Pau Montesinos; Hamid Sayar; Maurizio Musso; Angela F Figuera Alvarez; Hana Safah; William Tse; Sang Kyun Sohn; Devendra Hiwase; Timothy Chevassut; Francesca Pierdomenico; Ignazia La Torre; Barry Skikne; Keshava Kumar; Qian Dong; Beach, CL; Herve Dombret;
PUBLICAÇÃO: 2020, FONTE: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, VOLUME: 20
INDEXADO EM: WOS
2
TÍTULO: An international phase 3 randomized, placebo-controlled study of CC-486 (oral azacitidine) maintenance therapy in patients with acute myeloid leukemia (AML) in complete remission (CR): The Quazar AML maintenance trial.
AUTORES: Gail J Roboz; Farhad Ravandi; Dominik Selleslag; Pau Montesinos; Andrew Wei; Kimmo Porkka; Antonio Almeida; Michael R Savona; Sanjay Ram Mohan; Jose F Falantes; Maria Teresa Voso; Keshava Kumar; Frederic Camus; Ignazia La Torre; Hagop Kantarjian; Barry Skikne;
PUBLICAÇÃO: 2015, FONTE: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 33, NÚMERO: 15
INDEXADO EM: WOS